C

Celltrion Pharm Inc
KOSDAQ:068760

Watchlist Manager
Celltrion Pharm Inc
KOSDAQ:068760
Watchlist
Price: 63 600 KRW -2.75%
Market Cap: 2.8T KRW

Celltrion Pharm Inc
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Celltrion Pharm Inc
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
C
Celltrion Pharm Inc
KOSDAQ:068760
Note Receivable
â‚©4.3B
CAGR 3-Years
-20%
CAGR 5-Years
-15%
CAGR 10-Years
3%
Yuhan Corp
KRX:000100
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Biopharmaceuticals Co Ltd
KRX:326030
Note Receivable
â‚©59.9m
CAGR 3-Years
-15%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Note Receivable
â‚©10.5B
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Note Receivable
â‚©4.1B
CAGR 3-Years
234%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Caregen Co Ltd
KOSDAQ:214370
Note Receivable
â‚©1B
CAGR 3-Years
2%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Pharm Inc
Glance View

Market Cap
2.8T KRW
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.

Intrinsic Value
26 382.05 KRW
Overvaluation 59%
Intrinsic Value
Price
C

See Also

What is Celltrion Pharm Inc's Note Receivable?
Note Receivable
4.3B KRW

Based on the financial report for Jun 30, 2025, Celltrion Pharm Inc's Note Receivable amounts to 4.3B KRW.

What is Celltrion Pharm Inc's Note Receivable growth rate?
Note Receivable CAGR 10Y
3%

Over the last year, the Note Receivable growth was 3 182%. The average annual Note Receivable growth rates for Celltrion Pharm Inc have been -20% over the past three years , -15% over the past five years , and 3% over the past ten years .

Back to Top